Comparative Pharmacology
Head-to-head clinical analysis: INCIVEK versus TYZEKA.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INCIVEK versus TYZEKA.
INCIVEK vs TYZEKA
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Inhibitor of the HCV NS3/4A serine protease, preventing cleavage of the HCV polyprotein, thereby inhibiting viral replication.
Telbivudine is a synthetic thymidine nucleoside analogue with activity against hepatitis B virus (HBV). It is phosphorylated intracellularly to the active triphosphate form, which competes with natural thymidine triphosphate for incorporation into viral DNA, causing chain termination and inhibition of HBV DNA polymerase (reverse transcriptase).
Incivek (telaprevir) is administered orally at a dose of 750 mg (two 375 mg tablets) three times daily (every 7-9 hours) with food (not low-fat).
600 mg orally once daily
None Documented
None Documented
Terminal elimination half-life ranges from 4 to 13 hours (mean ~7 hours) in healthy volunteers; prolonged to 10-20 hours in HCV-infected patients.
Terminal elimination half-life is approximately 15 hours (range 12-20 hours) in patients with normal renal function; half-life is prolonged in renal impairment, requiring dose adjustment.
Approximately 91% of the radiolabeled dose is recovered in feces (79% as unchanged drug) and 9% in urine (1% as unchanged drug).
Renal excretion of unchanged drug accounts for approximately 40% of the administered dose; biliary/fecal excretion accounts for approximately 60%.
Category C
Category C
Antiviral
Antiviral, Hepatitis B